Series RIKV 25 0820RIKV 25 1119Settlement Date 05/21/202505/21/2025Total Amount Allocated (MM) 2,6808,200All Bids Awarded At (Price / Simple interest) 98.067/7.79896.214/7.783Total Number of Bids Received 923Total Amount of All Bids Received (MM) 10,13018,300Total Number of Successful Bids <td colspan="3" style="border-right: solid black 1pt ; border-left: solid black 1pt ...

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of me ...

WASHINGTON, May 19, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced that B. Douglas Bernheim, the Edward Ames Edmonds Professor of Economics at Stanford University, has affiliated with its subsidiary Compass Lexecon. Dr. Bernheim is an expert in industrial organization, mergers, behavioral economics, game theory and financial economics. Throughout his career, he has distinguished himself as a highly sought-after expert witness who has testified in many of the most important antitru ...

Revenues Increased 21% Year-over-Year with Adjusted EBITDA of $7.6 Million Reiterates Guidance for 2025 PETAH TIKVA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the first quarter, ended March 31, 2025. First Quarter 2025 Financial Highlights Revenues of $92million, up 21% compared with $76.1million in Q12024;GAAP operating loss of $2.7 million,c ...

Core Viewpoint - FEMSA has entered into an accelerated share repurchase (ASR) agreement to repurchase $250 million of its American Depositary Shares (ADS) to enhance capital returns to shareholders [1][2]. Group 1: ASR Agreement Details - The ASR agreement involves an initial delivery of 483,559 ADSs on May 20, 2025 [1]. - The total number of shares repurchased will depend on the daily volume-weighted average price of the ADS during the agreement term, minus a discount [2]. - The final settlement of the ASR is expected to be completed by the third quarter of 2025 [2]. Group 2: Company Overview - FEMSA operates in the retail industry through its Proximity Americas Division, which includes the OXXO small-format store chain, and Proximity Europe, which operates Valora [3]. - The company also has a Health Division that includes drugstores and digital financial services initiatives [3]. - In the beverage sector, FEMSA is the largest franchise bottler of Coca-Cola products globally by volume [3]. - FEMSA employs over 392,000 people across 18 countries and is recognized in various sustainability and ESG indexes [3].

Core Viewpoint - Regeneron Pharmaceuticals has successfully bid for the assets of 23andMe Holding Co. for $256 million, aiming to enhance its leadership in genetics-guided research and drug development, pending bankruptcy court and regulatory approvals [1][2][3] Group 1: Acquisition Details - The planned acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and Biobank assets, with the transaction expected to close in Q3 2025 [1] - Regeneron will operate 23andMe as a wholly owned subsidiary, continuing its consumer genomics services while excluding the Lemonaid Health business from the purchase [3][4] Group 2: Commitment to Data Privacy - Regeneron emphasizes its commitment to the privacy and ethical use of 23andMe's customer data, planning to work with an independent Customer Privacy Ombudsman to ensure compliance with privacy policies and laws [2][3] - The company has a proven track record in large-scale data management, having linked deidentified DNA sequences from nearly three million participants to electronic health records [2][3] Group 3: Strategic Vision - Regeneron aims to leverage its expertise in genetic research to support 23andMe's mission of helping individuals understand their DNA and improve personal health [2][3] - The acquisition aligns with Regeneron's broader strategy to utilize genetics research for advancing medical treatments and improving societal health outcomes [2][3][4]

Core Viewpoint - 23andMe has entered into a definitive agreement to sell itself to Regeneron Pharmaceuticals for $256 million, ensuring compliance with privacy policies and consumer data protection [2][3][5]. Group 1: Transaction Details - The sale includes the acquisition of substantially all assets of 23andMe, specifically the Personal Genome Service (PGS) and Total Health and Research Services business lines, while excluding the Lemonaid Health subsidiary [3]. - The transaction is subject to court approval and is expected to close in the third quarter of 2025, following a court hearing scheduled for June 17, 2025 [5]. - The auction for the sale was completed on May 16, 2025, as part of 23andMe's Chapter 11 proceedings [5]. Group 2: Privacy and Compliance - Regeneron has committed to adhere to 23andMe's privacy policies and applicable laws, ensuring that customer personal data will be processed in accordance with existing consents and security measures [2][4]. - An independent Consumer Privacy Ombudsman will review the transaction's impact on consumer privacy and report to the court by June 10, 2025 [4]. Group 3: Company Statements - Mark Jensen, Chair of 23andMe's Board, expressed satisfaction with the transaction, highlighting its potential to maximize business value while protecting customer privacy [3]. - George D. Yancopoulos from Regeneron emphasized the company's commitment to safeguarding genetic data and enhancing 23andMe's mission to help individuals understand their DNA [4].

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Danske Bank A/S(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose r ...

In accordance with Festi’s remuneration policy, a share option plan, approved at the Company’s Annual General Meeting on March 6, 2024, is in effect based on Article 10 of the Income Tax Act No. 90/2003. The share option plan is valid for a period of three years, i.e., until May 2027, and applies to all permanent employees of the Festi Group. The objective of the plan is to align the interests of employees with the performance and long-term goals of the Company and its shareholders. Implementation of the sh ...

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be h ...